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An antiserum at!ainsl a I~ptide of the cytoplasmic tail of the M, 46000 mannose 6.phosphor© receptor is descril~d which recoljni~¢s preferentially 
the tctrameric v~rsus th~ dimerit: form of this receptor, This indicate~ that the conformation of the cytoplasmlc tail, whi¢l~ hatbours iltnals necessary 
for the trafficking ortIw receptor, dcp*nds on the tlUatcrnary stru~ttmre ofth~ receptor, 
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1. INTRODUCTION 
The Mr 46000 mannose 6-phosphate receptor (MPR 
46) is one of the receptors that recognize mannose 
6-phosphate residues on lysosomal proteins and 
mediate the transport of these proteins to the lysosomes 
(for review see [1,2]). The MPR 46 is a transmembrane 
protein with a single membrane-spanning domain, The 
extracytoplasmic domain is sufficient to bind the 
ligands and to form dimers [3], while the cytoplasmic 
domain contains transport signals necessary for the 
routing of the receptor [4-6]. Monomer]c, dimeric and 
tetrameric forms of the receptor have been isolated. 
The equilibrium between these forms is controlled by 
pH, ligand binding and receptor concentration [7]. 
These factors are subject to variations during the cycl- 
ing of the receptor between the site, where ligands bind 
to the receptor (presumably Golgi complex) and the 
site, where the ligands dissociate (presumably a 
prelysosomal organelle linked to the endocytotic route). 
This raises the possibility that the quaternary structure 
of the MPR 46 not only changes during the cycling bet. 
wren different compartmems, but contributes to the 
trafficking of the receptor [81. 
In the present study we have analyzed antibodies rais- 
ed against peptides of the cytoplasmic tail of MPR 46 
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for their reactivity with dimeric and tetrameric forms of 
the MPR 46. One of the peptide-specific antisera 
recognized preferentially the tetranteric receptor, in- 
dicating that the conformation of the cytoplasmic tail 
depends on the quaternary structure of MPR 46. This 
observation lends further support to the notion that the 
trafficking of the receptor may be controlled by its 
quaternary structure. 
2. MATERIALS AND METHODS 
2,1 Peptirle.specific antisem 
Peptides corresponding to residues 7-21 (peptide A) and 38-52 
(t~eplide 13) of tire cytoplasmic tail of MPR 45 (tl~e numbering of the 
tail starts with Arg-212, [9]) were synthesized us]rIg F.rnoc.protected, 
PyBOP- (benzotriazol.l.yl.oxy-trls.pyrrolidinol~hosl~honiurn hexa- 
fluorophosphate.) activated amino acids and an automatic peptide 
synthesizer (Milligcn 9050, Eschborn, Germany). The peptides were 
purified by reverse.phase chromatogra l~hy atad conjugated to keyhole 
limpet hemocyanin using glutaraldehyde asdescribed [10]. The con- 
jugate (corresponding to 0.25 mR peptide) was mixed with Freunds 
corn plete (first injection) or incomplete (booster injections) adjuvant 
and subcutaneously injected into rabbits. Booster injections were 
given 4 weeks after the first injection in biweekly intervals For 
purification of peptide-specific antibodies, 7.6 and 6.4 mg of peptide 
A and B, respectively, was coupled to I ml of Aft]gel 10 (Bio-Rad 
Mlinchen, Germany) according to the manufacturers instructions 
Affinity purification of antibodies was performed as described [11]. 
2.2. Separation of dbnerie and tetmmeric lt2~IJMPR 46 
MPR 46 purified from human liver was led]hated, and dimeric and 
tetrameric forms were separated by sucrose density centrifugation as 
described [7]. The quaternary structure was controlled by cross. 
linking of the dimeric and tetrameric forms with 0.6 mM disuc. 
cinimidyl suberate followed by SDS-PAGE [71, 
2,3. lmmunoprectpitation of [t2511MPR 46 
[l~Sl]MPR 46, 10 000 cpm, was incubated at 4~C with I t~i an- 
tiserum in 0.25 ml 0,1 M Tris-HCI, 1% Triton X-100, pH 7.5. Im- 
munoprecipitation was performed overnight with preparations con- 
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3. RESULTS 
Synthetic pcptides corresponding to residues 7-21 
(peptide A) and 38-52 (pcptidc B) of the cytopltrsmic 
tail of MPR 46 were conjugated to hcmocyarrin and us. 
cd for immunization of rabbits. For both pcptides the 
algorithm of Jamcson and Wolf [12] predicted a high 
antigenicity, and pcptide A had earlier been shown to bc 
antigenic [IO]. Antibodies precipitating (‘2JI]MRP 46 
were detectable after the third (pcptidc A) and sixth 
(peptide B) injection of the conjugates. Maximal nn- 
tibody levels were obtained after one to two further 
booster injections. Affinity chromatography on 
peptide-Affigel IO columns yielded 2 and 0,25 mg im- 
munogobulin using 1 ml of antiserum against peptidc A 
and B, respectively. 
The specificity of the antisera against peptides A and 
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Fig, 1. Immunoprecipitation of [lz51]MPR 46. [‘*‘I]MPR 46 was in- 
cubated with antiserum against peptide A @Peptide A) or MPR 46 
(wMPR 46) (see [13)). Where indicated 3.9 j&ml peptide A or B were 
present. The immune complexes were separated by SDS-PAGE. The 
part of the fluorogram containing the band of MPR 46 is shown. 
Fig. 2. Immunoprecipitation of [“S]MPR 46. Extracts of 
metabolically labelled BI-IK cells overexpressing MPR 46 were in- 
cubated with antiserum against MPR 46 ((u-MPR 46), peptide A or B 
@Peptide A or B) or preimmune serum. The immune complexes were 
separated by SDS-PAGE. The position of 14C-methylated molecular 
mass standards (New England Nuclear, Dreieich, Geemany), given in 
kDa, and of MPR 46 (arrowhead) are indicated. 
tially all of the [“S)MPR 46 can be precipitated with 
higher amounts of the pcptidc-specific nntixern (not 
shown), 
tetramers. In cells the dimeric form prevails, while in 
preparations of purified receptor the fraction of 
tetrameric form increases [7,8]. Preliminary ex- 
periments with mixtures of dimcric and tetrameric 
MPR 46 rcvcaled that compared to antisera against 
MPR 46 and tail peptide B, the antiserum against he 
tail peptidc A reacted preferentially with the tctramcric 
form of MPR 46. Dimeric and tctramcric [‘Z51]MPR 46 
were therefore separated by sucrose density centrifuga- 
tion and their binding to antisera gainst MPR 46 and 
tail peptide A was compared. The data of 3 independent 
binding expcrimcnts arc summarized in Table I, and 
one of these experiments i shown in Fig, 3. Using the 
antiserum against MPR 46, twice as much radioactivity 
was found in the immunqprecipitate of tctrameric MPR 
46 compared to that of dimcric MPR 46. Since the 
tetrameric MPR 46 contains twice as much radioactivity 
per no1 than the dimeric MPR 46, comparable numbers 
of dimeric and tetrameric receptor forms were bound 
by the antiserum against MPR 46. Under the same con- 
ditions, using the antiserum against ail pcptide A, 4 
times more radioactivity was found in the im- 
munoprecipitate of tctrameric MPR 46 compared to 
that of dimeric MPR 46. This indicates that on a molar 
basis, twice as many antibody-receptor complexes were 
formed between the peptide-specific antiserum and 
tetrameric MPR 46 than between the peptide-specific 
antiserum and dimeric MPR 46. 
The cytoplasmic tail of MPR 46 is essential for the traf- 
ficking of this receptor. Truncated receptor: Iacking a 
cytoplasmic tail accumulate at the cell surface, in- 
dicating the sequences necessary tsr cndoeyrosis reside 
in the eytoplasmic tail [4-61. Other signals required for 
the cycling of this receptor between the Golgi apparatus 
Fig. 3. Ilnlnunoprecipitation of dimcric and tetrameric [‘L51]MPR 46. 
Dimeric or tetrameric [‘251]MPR 46 was incubated with preimmune 
serum (l), antiserum raised against peptide A (2), or against MPR 46 
(3). The immune complexes were nnalyscd by SDS-PAGE. The 
numbers below the la~rre give the amount of I”‘I]MPR 46 precipitated 
by the peptidr-specific a;W.erum as a fraction of the [‘Z51]MPR 46 
precipitated by the antiserum against MPR 46. All receptor prcpara- 
tions contain small amounts of receptor homodimers which are resis- 
tant to boiling in SDS and dithiothreitol (see [14]). The position OT 
monomeric (M) and dimeric (D) MPR 46 is indicated. 
und p~elyxoromal ~gan~ller linked rn the rrndacytic 
route nrc also suspected to rrxiduf in the cytnplaxmio 
tail. It is therrfore of interest to nsrc that the reiilctivity 
of a tail-specific antibody dcpcnds on thr quatcrnary 
structure of the receptor. The prcfcrentinl binding sf 
the antibody against tail pcptide A co tctramcric MPR 
46 indicrrtcs thnt the epitope on tnil rrsiduez+ 7-11 either 
becomes more nccessiblc to e\ntibadies ar chnnges its 
conformation, when dimsric MPR 46 associates to 
tetramcric MPR 46. This indicates chat $1 change af the 
qunternnry structure of MPR 46 affects the structure of 
its eyroplasmic tail and may hcnee: cxpesc or disclose 
siynnls required for the trafficking of the receptor. 
Previous studies have riuygcsted that changes of the 
quaternary structure of MPR 46, which in turn could 
affect its signal-mccliated trafficking, can occur during 
the cycling of the receptor between its l&and-binding 
site in the Golgi appaeatus and its lignnd delivery site in 
prelysosomcs. At 37°C the quaternary structure of 
MPR 46 is highly sensitive to changes in pH, presence 
of ligands and changes of receptor concentration in a 
manner that would fnvour the association of the rcccp- 
tar in the Golgi apparatus and the dissociation in acidic 
prrlysosomal organelles [$I. In summary, this study 
provides the first cvidcncc that the structure of the 
cytoplasmic tail, which itself is dispcnsible for 
oligomcrization of MPH 46, depends on the quaternary 
structure of the rccr#or. 
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